RxDoctor Payments Data

Steven Kaplan, MD

Family Medicine · Clayton, CANPI 1518073030

Payments from drug & device makers

$6,279in general payments, 2019–2025

Across 374 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$883
  • Pfizer$485
  • Amarin Pharma, Inc.$428
  • Antares Pharma, Inc.$371
  • Novo Nordisk$339
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$6,250100%
  • Education$60%
  • Entertainment$230%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,279 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$287,508
Medicare patients
502
Services billed
8,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin55$84,165
MounjaroTirzepatide55$66,325
TrulicityDulaglutide65$64,105
OzempicSemaglutide59$54,126
EliquisApixaban42$44,450
LinzessLinaclotide20$20,537
MyrbetriqMirabegron33$18,667
JanuviaSitagliptin Phosphate13$16,357
Testosterone88$13,814
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,019
Sumatriptan Succinate37$7,379
Synjardy XrEmpagliflozin/Metformin Hcl12$6,968
Rosuvastatin Calcium311$5,415
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen236$5,046
Atorvastatin Calcium363$4,271

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$283$130,430120 claims
Boehringer IngelheimJardiance, Synjardy Xr$284$91,13367 claims
Novo NordiskOzempic$339$54,12659 claims
PfizerEliquis$485$44,45042 claims
AbbVieLinzess$1,246$20,53720 claims
Astellas Pharma US IncMyrbetriq$79$18,66733 claims
MerckJanuvia$87$16,35713 claims
GSKTrelegy Ellipta$97$11,01917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Clayton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →